$GILD
AI AnalysisGenerated on May 11, 2026
AI Score
Hold$GILD
Gilead Sciences
$GILDNASDAQHealthcareLarge-Cap
Gilead develops and commercializes antiviral therapies including HIV, hepatitis, and COVID-19 treatments.
Market Cap
$108.0B
Revenue (TTM)
$27.8B
+5.0%
Net Income (TTM)
$5.5B
+10.0%
EPS (TTM)
$4.40
P/E Ratio
22.0
Dividend Yield
3.2%
52-Week Range
$65-$95
Beta
0.52
Dimension Scores
Fundamental
74Technical
66Sentiment
70Risk / Reward
76Momentum
62Financial Health
Profitability
79strong
Growth
65moderate
Liquidity
84strong
Solvency
76strong
Efficiency
72strong
Valuation, technical analysis, investment thesis, risk assessment and more for $GILD
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.